Claims
- 1. A compound of the formula I
- 2. The compound of the formula I according to claim 1, wherein Ra is a R2NR3— group, wherein
R2 is a C1-4-alkyl group optionally substituted by a carboxy, C1-6-alkyloxycarbonyl, benzyloxycarbonyl, methylsulfonylaminocarbonyl, or 1H-tetrazol-5-yl group, a C2-4-alkyl group substituted at a carbon which is other than the one at the α-position relative to the adjacent nitrogen atom, by a hydroxy, benzyloxy, carboxy-C1-3-alkylamino, C1-3-alkoxycarbonyl-C1-3-alkylamino, N-(C1-3-alkyl)-carboxy-C1-3-alkylamino, or N-(C1-3-alkyl)-C1-3-alkoxycarbonyl-C1-3-alkylamino group, and R3 is a propargyl group, wherein the unsaturated moiety is not linked directly to the nitrogen atom of the R2NR3— group, is a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, or is a pyridinyl group, and or a tautomer or salt thereof.
- 3. The compound of the formula I according to claim 1, wherein R3 is a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, or is a pyridinyl group, or a tautomer or salt thereof.
- 4. The compound of the formula I according to claim 1, wherein R3 is a propargyl group, wherein the unsaturated moiety is not linked directly to the nitrogen atom of the R2NR3— group, or a tautomer or salt thereof.
- 5. The compound of the formula I according to claim 1, wherein R3 is a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, or a tautomer or salt thereof.
- 6. The compound of the formula I according to claim 1, wherein R3 is a pyridinyl group, or a tautomer or salt thereof.
- 7. The compound of the formula I according to claim 1, wherein A is a carbonyl group linked to the benzo moiety of the group Het, or a tautomer or salt thereof.
- 8. The compound of the formula I according to claim 1, wherein A is a sulfonyl group linked to the benzo moiety of the group Het, or a tautomer or salt thereof.
- 9. The compound of the formula I according to claim 1, wherein Rb is a hydrogen atom, or a tautomer or salt thereof.
- 10. The compound of the formula I according to claim 1, wherein b is a hydroxy, C1-9-alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-C1-3-alkylbenzoyl or nicotinoyl group, wherein the ethoxy moiety in the 2-position of the abovementioned C1-9-alkoxycarbonyl group is unsubstituted or additionally substituted by a C1-3-alkylsulfonyl or 2-(C1-3-alkoxy)-ethyl group, or a tautomer or salt thereof.
- 11. 3-Methyl-2-[(4-amidinophenyl)thiomethyl]imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide hydrochloride, or a tautomer or salt thereof.
- 12. 3-Methyl-2-[N-(4-amidinophenyl)aminomethyl]imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide hydrochloride, or a tautomer or salt thereof.
- 13. 3-Methyl-2-[(4-amidinophenyl)thiomethyl]imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)amide hydrochloride, or a tautomer or salt thereof.
- 14. 3-Methyl-2-[N-(4-amidinophenyl)aminomethyl]imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)amide hydrochloride, or a tautomer or salt thereof.
- 15. A physiologically acceptable salt of a compound according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.
- 16. A pharmaceutical composition comprising a compound according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or a tautomer or salt thereof, and a pharmaceutically acceptable carrier or diluent.
- 17. A method for the prophylaxis or treatment of venous and arterial thrombotic disease which comprises administering an antithrombotic amount of a compound according one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or a physiologically acceptable salt thereof.
- 18. The method of claim 17, wherein the thrombotic disease is selected from the group consisting of: deep leg vein thrombosis, reocclusion after a bypass operation or angioplasty (PT(C)A), occlusion in peripheral arterial disease, pulmonary embolism, disseminated intravascular coagulation, coronary thrombosis, stroke, and the occlusion of a shunt or stent.
- 19. A method for providing antithrombotic support in thrombolytic treatment utilizing rt-PA or streptokinase, which comprises administering a therapeutically effective amount of a compound according one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or a physiologically acceptable salt thereof.
- 20. A method for preventing metastasis or the growth of clot-dependent tumors, which comprises administering a therapeutically effective amount of a compound according one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or a physiologically acceptable salt thereof.
- 21. A method for treating or preventing fibrin-dependent inflammatory processes, which comprises administering a therapeutically effective amount of a compound according one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or a physiologically acceptable salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
197 06 229.6 |
Feb 1997 |
DE |
|
197 51 939.3 |
Nov 1997 |
DE |
|
RELATED APPLICATIONS
[0001] This is a continuation of U.S. Ser. No. 09/544,931, filed Apr. 6, 2000, which is a division of U.S. Ser. No. 09/025,690, filed Feb. 18, 1998, now U.S. Pat. No. 6,087,380, issued Jul. 11, 2000, which claimed benefit of prior filed and copending U.S. provisional application Serial No. 60/044,421, filed Apr. 29, 1997.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60044421 |
Apr 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09025690 |
Feb 1998 |
US |
Child |
09544931 |
Apr 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09544931 |
Apr 2000 |
US |
Child |
10192041 |
Jul 2002 |
US |